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Abstract:  Hepatic  diseases,  like  viral  hepatitis,  autoimmune  hepatitis,  hereditary 
hemochromatosis, non-alcoholic fatty liver disease (NAFLD) and Wilson’s disease, play 
an  important  role  in  the  development  of  liver  cirrhosis  and,  hence,  hepatocellular 
carcinoma. In this review, the current treatment options and the molecular mechanisms of 
action of the drugs are summarized. Unfortunately, the treatment options for most of these 
hepatic diseases are limited. Since hepatitis B (HBV) and C (HCV) infections are the most 
common causes of liver cirrhosis and hepatocellular carcinoma, they are the focus of the 
development of new drugs. The current treatment of choice for HBV/HCV infection is  
an  interferon-based  combination  therapy  with  oral  antiviral  drugs,  like  nucleos(t)ide 
analogues, which is associated with improving the therapeutic success and also preventing 
the development of resistances. Currently, two new protease inhibitors for HCV treatment 
are expected (deleobuvir, faldaprevir) and together with the promising drug, daclatasvir 
(NS5A-inhibitor, currently in clinical trials), adequate therapy is to be expected in due 
course (circumventing the requirement of interferon with its side-effects), while in contrast, 
efficient HBV therapeutics are still lacking. In this respect, entry inhibitors, like Myrcludex B, 
the lead substance of the first entry inhibitor for HBV/HDV (hepatitis D) infection, provide 
immense potential. The pharmacokinetics and the mechanism of action of Myrcludex B are 
described in detail. 
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1. Introduction 
Liver  diseases,  such  as  viral  hepatitis,  autoimmune  hepatitis,  hereditary  hemochromatosis,  
non-alcoholic fatty liver disease (NAFLD) and Wilson’s disease, are associated with an increased risk 
for the development of liver cirrhosis and hepatocellular carcinoma. Additional risk factors are toxins, 
like alcohol and aflatoxin. The main risk factors for the development of liver cirrhosis are summarized 
in Figure 1. 
Figure  1.  Risk  factors  for  the  development  of  liver  cirrhosis  with  subsequent 
hepatocellular carcinoma. 
 
While the prevalence of autoimmune hepatitis and metabolic disorders, like hemochromatosis and 
Wilson’s disease, is vanishingly low, more than 500 million people worldwide are persistently infected 
with  the  hepatitis  B  virus  and/or  hepatitis  C  virus  [1].  Up  to  one  million  people  die  due  to  
hepatitis B (HBV) infections and their consequences annually [2]. As the disease is only associated 
with  nonspecific  symptoms  (the  most  common  ones  being  malaise  and  fatigue)  [3],  the  risk  of 
developing  liver  cirrhosis  or  hepatocellular  carcinoma  is  increased.  An  estimated  57%  of  the  
total  hepatic  cirrhosis  and  78%  of  the  primary  hepatocellular  carcinomas  are  the  result  of  
hepatitis B/hepatitis C (HCV) infections [2]. This highlights the importance for hepatitis infections to 
be diagnosed at an early stage to enable an optimal treatment. 
Hepatitis  infections  can  be  caused  by  a  wide  range  of  viruses.  Primary  hepatotropic  viruses 
(hepatitis  A,  B,  C,  D  and  E)  are  distinguished  from  other  viruses,  like  Epstein-Barr  virus  or 
cytomegalovirus.  Table  1  summarizes  the  differences  of  the  family,  genome,  transmission  path, 
incubation period and the possible immunoprophylaxis of the primary hepatotropic viruses. Int. J. Mol. Sci. 2014, 15  7502 
 
Table 1. Characteristics of hepatotropic viruses. 
Characteristics 
Hepatitis A 
virus 
Hepatitis B 
virus 
Hepatitis C 
virus 
Hepatitis D 
virus 
Hepatitis E 
virus 
family  Picornaviridae  Hepadnaviridae  Flaviviridae  unknown  Hepeviridae 
genome 
single-stranded 
RNA 
double-stranded 
DNA 
single-stranded 
RNA 
single-stranded 
RNA 
single-stranded 
RNA 
transmission route  fecal-oral 
parenteral, 
sexual, perinatal 
parenteral, 
sexual, perinatal 
parenteral, 
sexual, perinatal 
fecal-oral 
incubation period  2–7 weeks  1–6 months  2–25 weeks  1–6 months  2–9 weeks 
immunoprophylaxis  active, inactive  active, inactive  not available  active, inactive  not available 
In  this  review, the treatment options for  the liver diseases  mentioned  above  and  their  possible 
results, namely liver cirrhosis and hepatocellular carcinoma, are discussed. 
2. Hepatitis 
2.1. Hepatitis A 
While  hepatitis  A  infection  is  not  associated  with  chronic  liver  disease  in  general,  older  and 
immunosuppressed people are susceptible to develop a fatal progression. Solid prophylaxis is possible, 
since hepatitis A is one of the best examples for vaccine-preventable infectious diseases in the world 
with several options for vaccination. The first effective vaccine against hepatitis A, Havrix™, was 
introduced  in  1992  [4].  Nowadays,  combination  vaccines  against  hepatitis  A/B  are  also  available 
(Twinrix™ GlaxoSmithKline GmbH & Co. KG, 80700 München, Germany). These immunizations are 
indicated for people with a high work-related risk of infection (e.g., medical staff) and for people in 
regions with a high rate of hepatitis A infections, such as Western Africa. 
2.2. Hepatitis B 
Hepatitis B is one of the most threatening infectious diseases with an estimated 300 million chronic 
carriers worldwide [5]. In most cases, acute hepatitis B infection is associated with a spontaneous 
recovery, the reason for which therapy is not recommended [6]. Indeed, patients with life-threatening 
liver diseases and those with high levels of HBV replication and active or advanced liver diseases 
should be treated. Other patients should be monitored to ensure initiation of treatment when indicated 
(markers  are  HBV  DNA  levels  and  transaminases  levels).  Treatment  of  chronic  hepatitis  B  is  
non-curative.  It  currently  relies  on  seven  registered  drugs  on  the  market  that  slow  down  
disease  progression  [7].  The  oldest  and  most  common  therapy  consists  of  interferon-α-2a  or  
peginterferon-α-2a.  Interferon  has  antiviral,  anti-proliferative  and  immunomodulatory  effects. 
Consequently, the therapy can suppress HBV replication and also induce remission of liver diseases. 
Interferons are applied either in their native form or after conjugation with PEG (polyethylene glycol). 
PEGylation of interferon-α-2a leads to a slower enzymatic depletion and renal clearance. Peginterferon 
is  also  superior  to  unmodified  interferon,  because  of  its  more  convenient  and  predictable  dosing 
schedule. Unfortunately, interferon therapy has also side-effects ranging from influenza-like illness, 
alopecia, leucopenia to thrombocytopenia. The most troublesome side-effect of interferon therapy is Int. J. Mol. Sci. 2014, 15  7503 
 
emotional lability, which manifests itself in anxiety, irritability and depression. Most of the side-effects 
cannot be predicted, but are reversible [8]. Nevertheless, interferon remains one of the first-line options 
for patients without cirrhosis [8]. In order to study the therapeutic success, patients receiving interferon 
therapy should have blood counts and liver panel monitored every four weeks and HBV DNA levels 
every 12 weeks. Unfortunately, all interferons have to be administered subcutaneously, whereas the 
alternative first-line option, the antiviral drugs, can be taken orally. Nowadays, five antiviral drugs are 
available: lamivudine (cytosine analogue), entecavir (guanosine analogue) and telbivudine (thymidine 
analogue), as well as the nucleotide-analogues, adefovir and tenofovir (both adenosine analogues), 
with a low prevalence of side-effects, but the risk of developing viral resistances and the disadvantage 
of a long-lasting treatment (the nucleos(t)ide analogues usually have to be administered for many 
years) [7]. Being prodrugs, these drugs are activated after their entry into the cell: nucleosides are 
triphosphorylated by cellular kinases, while nucleotides, which possess one phosphate group, have to 
be phosphorylated twice. In their respective triphosphate forms, they block the DNA-polymerase of the 
HBV and cause chain termination. Nucleos(t)ide therapy should be attended by liver panel monitoring 
every 12 weeks and HBV levels every 12–24 weeks. In addition, the serum creatinine and phosphorus 
blood levels should be tested every 12 weeks for patients receiving adefovir or tenofovir, because of 
their nephrotoxicity. In 2009, the American Association for the Study of Liver Diseases (AASLD) 
proclaimed key changes for first-line and second-line antiviral agents. In two double-blind randomized 
trials,  tenofovir  showed  superiority  when  compared  to  adefovir  as  related  to  a  higher  number  of 
patients with undetectable serum HBV DNA levels after 48 weeks of treatment and less occurrence of 
resistances up to 96 weeks of treatment [9]. Due to their advantages (see Table 2), tenofovir and 
entecavir are used as first-line oral antiviral drugs nowadays. 
Table 2. Approved drugs for oral HBV treatment. 
Characteristics  Lamivudine  Tenofovir  Adefovir  Entecavir  Telbivudine 
year of approval  1999  2001  2002  2006  2007 
resistance after 
five years 
ca. 70%  not found yet  ca. 30%  ca. 1%  ca. 22% 
medical 
assessment 
well tolerated, 
main concern: 
resistance 
less 
nephrotoxic 
than adefovir 
nephrotoxic, 
less prone to 
resistance than 
lamivudine 
well tolerated, 
more potent than 
lamivudine and 
adefovir 
well tolerated, 
high potency, 
resistances appear 
after one year 
The currently approved medications (shown in Figure 2) are non-curative, and the nucleos(t)ide 
analog-based treatment of chronic HBV infection frequently leads to the development of resistances. 
Consequently, alternative strategies and new drugs that target different steps of the HBV replication 
cycle  are  in  demand  to  improve  the  treatment  outcome  [10].  For  example,  viral  entry  inhibition 
represents a potent therapeutic concept to combat viral infections both in the acute and the chronic 
phase. One approach could be the use of acylated peptides derived from the large HBV envelope 
protein. As shown in Table 1, HBV is a member of the Hepadnaviridae, the smallest enveloped DNA 
viruses that replicate by reverse transcription of a pregenomic RNA intermediate. During assembly of 
the nucleocapsid, HBV acquires three viral envelope proteins, termed large (L), middle (M) and small (S). 
These envelope proteins are encoded in one open reading frame and share the S-domain, which is Int. J. Mol. Sci. 2014, 15  7504 
 
required for membrane anchoring. In addition to the S-domain, M contains an N-terminal hydrophilic 
extension of 55 amino acids (preS2), while L is further extended by 107, 117 or 118 amino acids 
(genotype-dependent), termed preS1. The myristoylated preS1-domain of L plays the key role in HBV 
and hepatitis delta virus (HDV) infectivity by mediating attachment and specific receptor binding [11]. 
Petersen et al. [12] showed that hepadnavirus infection can be efficiently restrained by subcutaneous 
application of HBV envelope protein-derived lipopeptides in vivo. Schieck et al. [11] demonstrated 
that HBV virus hepatotropism is mediated through specific binding of the myristoylated N-terminal 
preS1-domain of the HBV L-protein to a hepatocyte specific, but at that time unknown, receptor. In 
2013, Chen et al. [13] proclaimed a sodium taurocholate cotransporting peptide (NTCP) as a potential 
viral receptor by identifying a stretch of 10 amino acids in the NTCP transmembrane domain as the 
motive directly interacting with the preS1 peptide. In the future, there is the necessity to understand the 
interaction  of  NTCP  with  HBV  envelope  proteins  and  other  cellular  proteins.  Schieck  et  al.  [11] 
furthermore showed that Myrcludex B, the lead substance of the first entry inhibitor for HBV/HDV 
infection, is a very attractive potential drug, because of its exclusive targeting of susceptible cells. This 
makes subcutaneous application of low doses possible. Another beneficial effect is the remarkable 
serum stability of the peptide and a half-life time of about 16 h in mice, 10 h in rats and 13 h in 
beagles.  Thus,  therapeutic  application  may  be  required  once  every  1–3  days  only.  The  peptide  is 
currently in Phase 1/2 clinical trials. An important task in the future will be the development of a 
formulation of Myrcludex B, which enables its oral administration. 
Figure 2. Drugs for HBV treatment. 
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Beyond the NTCP receptor, other receptors that block HCV entry into the cell have been identified. 
Lupberger et al. [14] identified the epidermal growth factor receptor and ephrin receptor A2 as host 
cofactors  for  HCV  entry,  and  in  2012,  Sainz  et  al.  [15]  proclaimed  the  Niemann-PickC1-like  1 
cholesterol  absorption  receptor  (NPC1L1)  as  a  new  hepatitis  C  virus  entry  factor,  since  NPC1L1 
expression  is  necessary  for  HCV  infection.  Ezetimibe,  an  Food  and  Drug  Administration-(FDA) 
approved NPC1L1 antagonist, which is nowadays generally used as a lipid-lowering agent, potently 
blocks HCV uptake in vitro via a virion cholesterol-dependent step prior to virion-cell membrane 
fusion  [16].  Together,  these  findings  hold  promise  for  the  future  that  viral  entry  inhibitors  could 
improve HCV treatment. 
2.3. Hepatitis C 
Approximately 180 million people are chronically infected with the hepatitis C virus, and HCV 
infections are one of the most common reasons for liver cirrhosis and hepatocellular carcinoma. There 
are six genotypes of the hepatitis C virus that can be distinguished. Most important are the Genotypes 1–3 
(Genotype 1 being the most common variant in the United States and Europe), which differ in their 
treatment  options  [6].  Acute  hepatitis  C  infection  remains  asymptomatic  in  most  cases,  but  is 
accompanied  by  the  risk  of  chronic  progression.  Hence,  it  is  generally  treated  with  interferon  α 
(PEGylated/non-PEGylated) [6], while the first-line treatment of chronic hepatitis C is a combination 
of  peginterferon-α-2a/2b  and  the  nucleoside  analogue,  ribavirin  [17].  The  dose  of  ribavirin 
administered and the duration of the treatment (48 weeks for Genotype 1, 24 weeks for Genotypes 2 
and 3) depends on the genotype of the HCV  virus. However, it is important to consider that the 
combination therapy shows more side-effects than the monotherapy. Because of its teratogenicity, 
ribavirin is contraindicated in pregnancy and the lactation period. It also shows hemolytic effects and a 
suppression  of  the  myocardium.  Since  peginterferon  plus  ribavirin  achieves  sustained  virological 
response in fewer than 50% of the patients with Genotype 1 infection, further therapies are required. 
The current therapeutic options for HCV Genotype 1 infections are shown in Figure 3 and include 
HCV protease inhibitors, like boceprevir and telaprevir, in addition to the interferon/ribavirin therapy. 
It was shown in patients with untreated chronic hepatitis C Genotype 1 infection that the addition of 
the protease inhibitor, boceprevir, to the standard treatment (peginterferon and ribavirin for 48 weeks) 
improves the response rate [18]. This triple therapy is not without side-effects, as it is associated with 
the  selection  of  resistant  viral  variants,  new  adverse  events  and  clinically  relevant  drug-drug 
interactions [19]. In 2013, two new drugs (sofosbuvir and simeprevir) received FDA approval. For this 
reason, the AASLD changed its recommendations for treatment-native patients with HCV Genotype 1 
infection (see Table 3). Sofosbuvir (Sovaldi™ GILEAD Sciences GmbH, 82152 Martinsried, Germany) 
is a uridine nucleotide analogue and a selective inhibitor of the nonstructural protein 5B (NS5B), a viral 
protein found in the hepatitis C virus [20]. As a prodrug, sofosbuvir is activated intracellularly by 
phosphorylation. The second drug, simeprevir (Olysio™ Janssen Therapeutics, Division of Janssen 
Products, LP, Titusville NJ 08560), is a noncovalent inhibitor of the non-structural protease NS3/4A [21]. 
While sofosbuvir seems to be well-tolerated, unfortunately, simeprevir shows structural analogy to 
sulfonamides, and this part of the molecule is suspected to cause side-effects, like skin reactions. Other 
promising treatment options are currently under clinical investigation and are expected to be available Int. J. Mol. Sci. 2014, 15  7506 
 
in the second half of 2014. The novel treatment options include the second generation HCV protease 
inhibitor, faldaprevir, and deleobuvir, an HCV polymerase inhibitor. Both are currently being tested in 
Phase 3 clinical trials. A recent study (STARTVerso™ Boehringer Ingelheim, 55216 Ingelheim am 
Rhein, Germany) [22] investigated an interferon-based triple therapy (faldaprevir, peginterferon-α-2a 
and ribavirin) showing that faldaprevir is well-tolerated and achieves a significantly higher sustained 
virologic response. Another study investigated the effect of treatment duration, deleobuvir dosage and 
the absence or presence of ribavirin [23]. On  the one hand, the absence of ribavirin could be an 
advantage, avoiding its severe side-effects, but on the other hand, as the study showed, the presence of 
ribavirin is a basic component for the success of these regimens. The latest drugs currently investigated 
in clinical trials are daclatasvir, an inhibitor of HCV replication with the non-structural protein 5A as 
the  target  (NS5A)  and  asunaprevir,  a  NS3  protease  inhibitor.  A  Phase  2a  study  showed  that  the 
combination of these two drugs was well tolerated and achieved high response rates in genotype 1b 
HCV infections [24]. These findings give rise to the hope for an adequate therapy in the future. 
Figure 3. Drugs for HCV treatment. 
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Table  3.  The  American  Association  for  the  Study  of  Liver  Diseases’  (AASLD) 
recommendations for the 12-week treatment of HCV genotype 1 infection. 
Treatment-naive patients eligible to receive interferon  Treatment-naive patients ineligible to receive interferon 
sofosbuvir (400 mg) daily  sofosbuvir (400 mg) daily 
weight-based ribavirin daily  simeprevir (150 mg) daily 
peginterferon on a weekly basis  with/without weight-based ribavirin 
2.4. Hepatitis D 
Hepatitis D virus (HDV) is a unique RNA virus that requires a helper function provided by HBV 
for replication. Thus, HDV can only replicate in patients infected with HBV. The clinical course of 
hepatitis D infection is more severe than that of other hepatitis viruses, so that therapy should always 
be initiated. Unfortunately, there is no effective therapy for hepatitis D infection available nowadays. 
Interferon therapy is only associated with therapeutic success in about 30% of the treatments [6]. 
Moreover, there is no evidence yet that the combination therapy with ribavirin is superior to interferon 
monotherapy [6]. Hence, the only efficient possibility is the prevention of hepatitis B infection by 
vaccination, as discussed in a prior section. 
2.5. Hepatitis E 
Hepatitis  E  virus  (HEV)  most  commonly  occurs  in  Southeast  Asia  and  parts  of  Africa,  
Central- and South America. Transmission of HEV occurs mainly by the fecal-oral route. Chronic 
progression is rare, and there was no specific therapy available; however, China’s State Food and Drug 
administration approved a vaccine (Hecolin™, Xiamen Innovax Biotech, Xiamen, China) in 2012 [25], 
and another vaccine is in clinical trials [26]. 
3. Others 
3.1. Autoimmune Hepatitis 
Autoimmune hepatitis is an inflammation of the liver of unknown cause. It reflects a complex 
interaction  between  triggering  factors,  autoantigens,  genetic  predispositions  and  immunoregulatory 
networks.  Up  to  40%  of  the  patients  suffering  from  autoimmune  hepatitis  develop  liver  
cirrhosis  [27].  The  treatment  of  choice  is a  combination  therapy  of  the  corticosteroid,  prednisone 
(immunosuppressive  and  anti-inflammatory  effects),  and  the  purine  analogue,  azathioprine.  The 
addition of azathioprine allows the lowering of the dose of prednisone. The combination therapy is 
associated  with  a  lower  occurrence  of  corticosteroid-related  side-effects,  such  as  osteoporosis  and 
hypertension [27]. Manns et al. [28] showed that the corticosteroid, budesonide, in combination with 
azathioprine,  induces  the  remission  of  autoimmune  hepatitis  more  effectively  than  the  prednisone 
combination therapy with a low rate of steroid-specific side-effects. As a consequence, the budesonide 
therapy might become the first-line therapy once further data appear. 
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3.2. Hereditary Hemochromatosis 
Hereditary hemochromatosis is an autosomal recessive disorder that leads to the accumulation of 
iron in the body as a result of mutations in a gene located on chromosome 6 (called the High Iron Fe 
(HFE)  gene)  [29].  Standard  treatment  consists  of  repeated  phlebotomy  to  induce  a  negative  iron 
balance  and  to  remove  excess  iron  stored  in  the  tissues.  Nutrition  has  only  a  low  influence  in 
hemochromatosis;  vitamin  C  should  be  avoided,  because  it  increases  iron  absorption,  while  the 
absorption of iron is decreased by black tea. Hutchinson et al. [30] showed that proton pump inhibitors 
can reduce the necessity to maintain phlebotomy by inhibiting the absorption of non-heme iron, so that 
treatments based on this mechanism may become available in the future. 
3.3. Non-Alcoholic Fatty Liver Disease (NAFLD) 
Non-alcoholic  fatty  liver  disease  (NAFLD),  which  is  characterized  by  insulin  resistance  and 
necroinflammation with or without centrilobular fibrosis, increases the risk of developing diabetes and 
metabolic syndrome, resulting in liver cirrhosis and liver-related death [31,32]. This highlights the 
importance of adequate NAFLD-therapy. On the one hand, non-pharmacological therapy options, like 
weight reduction, physical activity and dietary changes, should be implemented. On the other hand, 
treatment  of  concurrent  metabolic  disorders,  like  obesity  by  statins  or  high  blood  pressure  by 
antihypertensive  agents,  like  beta-blockers,  is  necessary.  Previous  studies  have  investigated  the 
possibility of treating NAFLD with pioglitazone, a thiazolidinedione that ameliorates insulin resistance 
and improves glucose and lipid metabolism in type 2 diabetes mellitus. Belfort et al. [31] showed that 
the administration of pioglitazone, in addition to diet, leads to metabolic and histologically visible 
improvement,  but  they  also  proclaimed  that  prolonged  studies  are  necessary.  Sanyal  et  al.  [33] 
compared  pioglitazone  with  vitamin  E  and  placebo  and  showed  that  there  was  no  benefit  of 
pioglitazone over placebo for the improvement in histologic features. Certainly, pioglitazone showed 
benefits  in  reducing  hepatic  steatosis  and  lobular  inflammation  and  an  improvement  in  insulin 
resistance and liver-enzyme levels. Nevertheless, alternative therapy options with an improvement in 
histologic features have to be developed in the future. 
3.4. Wilson’s Disease 
Wilson’s disease is an autosomal recessive disorder of copper metabolism, which is caused by the 
absence or dysfunction of a copper transporting enzyme (P-type ATPase encoded on chromosome 13) [34]. 
It  leads  to  a  decrease  in  biliary  copper  excretion  and  finally  to  hepatic  cirrhosis  and  neuronal 
degeneration. Therapeutic options include a diet to avoid copper-rich food (chocolate, mushrooms and 
Crustacea), as well as administration of the copper chelating agents, penicillamine (which is the drug 
of  choice,  but  also  shows  severe  side-effects)  and  trientine  dihydrochloride,  which  leads  to  the 
excretion  of  copper  in  the  urine  [35].  Maintenance  therapy  of  successfully  treated  symptomatic 
patients can also be accomplished by zinc. Zinc is a metallothionein inducer (a cysteine-rich protein 
that is an endogenous chelator of metals) with the ability to block the intestinal absorption of copper [36]. 
   Int. J. Mol. Sci. 2014, 15  7509 
 
4. Liver Cirrhosis and Hepatocellular Carcinoma (HCC) 
4.1. Liver Cirrhosis 
Liver cirrhosis is a result of advanced liver diseases. Perz et al. [2] showed that in about 57% of the 
cases, liver cirrhosis was caused by HBV/HCV infection. Hence, prevention of liver cirrhosis and 
HBV/HCV  infection is  crucial, considering  that  about  78%  of hepatocellular carcinoma (HCC) is 
attributable  to  HBV/HCV.  The  treatment  of  choice  is  the  avoidance  of  boosting/triggering  
factors  (alcohol,  drugs,  etc.)  and  the  simultaneous  therapy  of  the  primary  diseases  (alcoholism, 
HBV/HCV infection). 
4.2. Hepatocellular Carcinoma (HCC) 
HCC is a major health problem, because no effective therapy is available. The main risk factors for 
the  development  of  HCC  are  type  2  diabetes,  alcoholism,  toxins,  such  as  aflatoxin,  and,  most 
particularly, the chronic HBV/HCV infections leading to liver cirrhosis, which is highly associated 
with HCC, as discussed above. Because of the poor response to cytostatic agents, the treatment of 
choice is surgical resection. Second-line options are percutaneous ethanol injection, radiofrequency 
ablation and liver transplantation. The only specific drug available is sorafenib (shown in Figure 4),  
a small molecule that inhibits tumor cell proliferation and angiogenesis. As a tyrosine kinase inhibitor, 
it blocks the autophosphorylation of the receptor tyrosine kinases like vascular endothelial growth 
factor (VEGFR), the platelet-derived growth factor receptor (PDGFR), and the proto-oncogenes c-Kit and 
RET. Studies [37] showed that in patients with advanced hepatocellular carcinoma, median survival 
and the time to radiologic progression were approximately three months longer for patients treated 
with sorafenib than for those given a placebo. A prospective possibility in HCC treatment could be 
resminostat, an oral available histone deacetylase inhibitor, because hypoacetylation of the histone 
protein H4 has been identified as a common early event in the pathogenesis of many human cancers, 
suggesting that increased histone deacetylase activity is a characteristic of malignant cells. Resminostat 
is currently being tested in Phase 2 studies as a monotherapy or in combination with sorafenib [38]. 
Figure 4. Drugs for hepatocellular carcinoma (HCC) treatment. 
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5. Conclusions 
Within the numerous hepatic diseases treatment is mainly required for viral hepatitis infections  
(in particular hepatitis B  and  C)  and  hepatocellular  carcinoma.  In recent years  new  drugs  for  the 
treatment of hepatitis C such as sofosbuvir and simeprevir have been approved by the FDA. These new 
drugs enable improved therapy of hepatitis C. In contrast, the current treatment options for hepatitis B 
still lack the performance required. Consequently novel treatment options such as entry inhibitors are 
still demanded. Unfortunately, despite enormous efforts the treatment options for hepatic tumors, in 
particular hepatocellular carcinoma, are still insufficient.  
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